STABL — Stayble Therapeutics AB Cashflow Statement
0.000.00%
- SEK20.11m
- SEK18.77m
Annual cashflow statement for Stayble Therapeutics AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
C2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Interim Report | ARS | Interim Report | ARS | PRESS |
Standards: | SAS | SAS | SAS | SAS | — |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -15.5 | -12.1 | -24.5 | -23.7 | -12.4 |
Non-Cash Items | — | -0.078 | — | 0.193 | — |
Other Non-Cash Items | |||||
Changes in Working Capital | -8.66 | 2.54 | -0.095 | 0.007 | -2.25 |
Change in Accounts Receivable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -24.1 | -9.63 | -24.6 | -23.5 | -14.7 |
Capital Expenditures | — | -0.001 | — | 0 | — |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | — | — | 0.001 | — | — |
Sale of Fixed Assets | |||||
Cash from Investing Activities | — | -0.001 | 0.001 | 0 | — |
Financing Cash Flow Items | -3.81 | -5.19 | 0 | -6.85 | -0.218 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 31.2 | 36.2 | 0 | 25 | 2.78 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 7.04 | 26.6 | -24.6 | 1.23 | -11.9 |